Abstract
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. Mutations of the DMD gene destabilize the dystrophin associated glycoprotein complex in the sarcolemma. Ongoing mechanical stress leads to unregulated influx of calcium ions into the sarcoplasm, with activation of proteases, release of proinflammatory cytokines, and mitochondrial dysfunction. Cumulative damage and reparative failure leads to progressive muscle necrosis, fibrosis, and fatty replacement. Although there is presently no cure for DMD, scientific advances have led to many potential disease-modifying treatments, including dystrophin replacement therapies, upregulation of compensatory proteins, anti-inflammatory agents, and other cellular targets. Recently approved therapies include ataluren for stop codon read-through and eteplirsen for exon 51 skipping of eligible individuals. The purpose of this chapter is to summarize the clinical features of DMD, to describe current outcome measures used in clinical studies, and to highlight new emerging therapies for affected individuals.
This is a preview of subscription content, log in via an institution.
References
Emery AE, Emery ML (1993) Edward Meryon (1809-1880) and muscular dystrophy. J Med Genet 30:506–511
Hoffman EP, Brown RH, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51:919–928
Emery AE (1991) Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord 1:19–29
Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N (2014) A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord 24:482–491
Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2:90–95
Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT (2006) Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 34:135–144
Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77–93
Mah JK, Selby K, Campbell C et al (2011) A population-based study of dystrophin mutations in Canada. Can J Neurol Sci 38:465–474
McDonald CM, Henricson EK, Abresch RT et al (2013) The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48:32–54
Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from international working group meetings. Clin Investig (Lond) 1:1217–1235
Henricson E, Abresch R, Han JJ et al (2013) The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 5. doi:10.1371/currents.md.9e17658b007eb79fcd6f723089f79e06
Mazzone ES, Messina S, Vasco G et al (2009) Reliability of the north star ambulatory assessment in a multicentric setting. Neuromuscul Disord 19:458–461
Escolar DM, Hache LP, Clemens PR et al (2011) Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77:444–452
McDonald CM, Henricson EK, Han JJ et al (2010) The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42:966–974
McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48:357–368
McDonald CM, Henricson EK, Abresch RT et al (2013) The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48:343–356
Pane M, Mazzone ES, Sivo S et al (2014) Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes. PLoS One 9:e108205
Mazzone E, Vasco G, Sormani MP et al (2011) Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study. Neurology 77:250–256
Mazzone ES, Pane M, Sormani MP et al (2013) 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS One 8:e52512
Steffensen B, Hyde S, Lyager S, Mattsson E (2001) Validity of the EK scale: a functional assessment of non-ambulatory individuals with Duchenne muscular dystrophy or spinal muscular atrophy. Physiother Res Int 6:119–134
Mercuri E, McDonald C, Mayhew A et al (2012) International workshop on assessment of upper limb function in Duchenne muscular dystrophy: Rome, 15-16 February 2012. Neuromuscul Disord 22:1025–1028
Mayhew A, Mazzone ES, Eagle M et al (2013) Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol 55:1038–1045
Pane M, Mazzone ES, Sivo S et al (2014) The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys. PLoS Curr 6. doi:10.1371/currents.md.a93d9904d57dcb08936f2ea89bca6fe6
Arechavala-Gomeza V, Kinali M, Feng L et al (2010) Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials. Neuromuscul Disord 20:295–301
Hathout Y, Brody E, Clemens PR et al (2015) Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 112:7153–7158
Willcocks RJ, Rooney WD, Triplett WT et al (2016) Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol 79:535–547
Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637–647
Mendell JR, Goemans N, Lowes LP et al (2016) Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann Neurol 79:257–271
Aartsma-Rus A, Ginjaar IB, Bushby K (2016) The importance of genetic diagnosis for Duchenne muscular dystrophy. J Med Genet 53:145–151
Finkel RS, Flanigan KM, Wong B et al (2013) Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy. PLoS One 8:e81302
Bushby K, Finkel R, Wong B et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50:477–487
Chicoine LG, Rodino-Klapac LR, Shao G et al (2014) Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin α2 surrogates. Mol Ther 22:713–724
Okada T, Takeda S (2013) Current challenges and future directions in recombinant AAV-mediated gene therapy of Duchenne muscular dystrophy. Pharmaceuticals (Basel) 6:813–836
Briggs D, Morgan JE (2013) Recent progress in satellite cell/myoblast engraftment – relevance for therapy. FEBS J 280:4281–4293
Ito M, Ehara Y, Li J, Inada K, Ohno K (2016) Protein-anchoring therapy of Biglycan for mdx mouse model of Duchenne muscular dystrophy. Hum Gene Ther. doi:10.1089/hum.2015.088
Guiraud S, Squire SE, Edwards B et al (2015) Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet 24:4212–4224
Wagner KR, McPherron AC, Winik N, Lee SJ (2002) Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol 52:832–836
Bogdanovich S, Krag TO, Barton ER et al (2002) Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418–421
Andreetta F, Bernasconi P, Baggi F et al (2006) Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J Neuroimmunol 175:77–86
Consalvi S, Mozzetta C, Bettica P et al (2013) Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat. Mol Med 19:79–87
Bettica P, Petrini S, D'Oria V et al (2016) Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26:643–649
Miyatake S, Shimizu-Motohashi Y, Takeda S, Aoki Y (2016) Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther 10:2745–2758
Bello L, Gordish-Dressman H, Morgenroth LP et al (2015) Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology 85:1048–1055
Heier CR, Damsker JM, Yu Q et al (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5:1569–1585
Gao QQ, McNally EM (2015) The Dystrophin complex: structure, function, and implications for therapy. Compr Physiol 5:1223–1239
Hernández-Ochoa EO, Pratt SJ, Lovering RM, Schneider MF (2015) Critical role of intracellular RyR1 calcium release channels in skeletal muscle function and disease. Front Physiol 6:420
Bowman CL, Gottlieb PA, Suchyna TM, Murphy YK, Sachs F (2007) Mechanosensitive ion channels and the peptide inhibitor GsMTx-4: history, properties, mechanisms and pharmacology. Toxicon 49:249–270
Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9:177–189
McNally EM, Kaltman JR, Benson DW et al (2015) Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, lung, and blood institute in collaboration with Parent Project Muscular Dystrophy. Circulation 131:1590–1515
Birnkrant DJ, Bushby KM, Amin RS et al (2010) The respiratory management of patients with Duchenne muscular dystrophy: a DMD care considerations working group specialty article. Pediatr Pulmonol 45:739–748
Morgenroth VH, Hache LP, Clemens PR (2012) Insights into bone health in Duchenne muscular dystrophy. Bonekey Rep 1:9
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Mah, J.K. (2018). An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy. In: Bernardini, C. (eds) Duchenne Muscular Dystrophy. Methods in Molecular Biology, vol 1687. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7374-3_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7374-3_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7373-6
Online ISBN: 978-1-4939-7374-3
eBook Packages: Springer Protocols